94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

Authors :: J. Alarcón
Pedro Sánchez-Rovira
M. Ramos
I. Fernandez-Perez
L. Rosell
C. Bueno
M. Martinez
L. de la Cruz-Merino
Noelia Martínez-Jañez
Ana Santaballa
Ariadna Tibau
Susana Bezares
Miquel Casas
Juan Antonio Virizuela
C.R. Albacar
Catherine M. Kelly
Joan Albanell
J. de la Haba-Rodríguez
F. Moreno
M. O' Connor
Source :: Annals of Oncology. 32:S63
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Fulvestrant
business.industry
Advanced breast
Cancer
Hematology
Palbociclib
Placebo
medicine.disease
Quality of life
Hormone receptor
Internal medicine
Medicine
Endocrine system
business
medicine.drug

Full Text Access

Tools